PharmaCyte Biotech Operating Income

As of the most recent data (July 2026), PMCB shows a operating income of $-5.5M. That compares with $-4M in the prior-year period — down 38.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PMCB's operating income is now $-5.5M (was $-4M) — a 38.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether PharmaCyte Biotech is outperforming or lagging.

Tracking PMCB's operating income over time shows whether PharmaCyte Biotech is scaling, shrinking, or reshaping that part of the business. The current reading is $-5.5M That compares with $-4M in the prior-year period — down 38.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has PharmaCyte Biotech's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-5.5M) with ownership activity and broader fundamentals.

PharmaCyte Biotech's operating income is $-5.5M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.